Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 2/20 | 0.49 |
| ▸ | MLYCD | O95822 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | MTOR | P42345 | 2/20 | 0.44 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.44 |
| ▸ | BACE1 | P56817 | 1/20 | 0.43 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | NAMPT | P43490 | 1/20 | 0.42 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1274028 | 0.94 | TACR1 (0.50) | TACR1MLYCDCYP3A4ALDH1A1MTOR | |
| SCHEMBL15844016 | 0.85 | TACR1 (0.58) | TACR1MLYCDALDH1A1MTORCACNA1H | |
| SCHEMBL20088438 | 0.79 | TACR1 (0.49) | TACR1MLYCDALDH1A1MTORCACNA1H | |
| SCHEMBL4576594 | 0.77 | CYP3A4 (0.48) | TACR1MLYCDCYP3A4ALDH1A1MTOR | |
| SCHEMBL5670894 | 0.77 | CYP3A4 (0.56) | TACR1MLYCDCYP3A4ALDH1A1MTOR | |
| Trifluoroacetic Acid SCHEMBL1295359 | 0.77 | RXRA (0.41) | TACR1CYP3A4ALDH1A1 | |
| Trifluoroacetic Acid SCHEMBL7760563 | 0.75 | AOC3 (0.60) | ALDH1A1HTTAOC3LMNATSHR | |
| SCHEMBL13452941 | 0.74 | MTOR (0.54) | TACR1MLYCDCYP3A4ALDH1A1MTOR | |
| SCHEMBL13884195 | 0.74 | L3MBTL1 (0.64) | MLYCDCYP3A4ALDH1A1BACE1AOC3 | |
| SCHEMBL11306116 | 0.74 | TACR1 (0.63) | TACR1MLYCDMTORBACE1BACE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120172392-A1 | AMINE-BASED AND AMIDE-BASED INHIBITORS OF SEMICARBAZIDE-SENSITIVE AMINE OXIDASE (SSAO) ENZYME ACTIVITY AND VAP-1 MEDIATED ADHESION USEFUL FOR TREATMENT OF DISEASES | SALTER-CID LUISA M (US) | 2012-07-05 | — | — | US | disclosed |
| EP-2283833-A2 | Amines and amides for the treatment of diseases | LA JOLLA PHARMACEUTICAL CO. (US) | 2011-02-16 | — | — | EP | disclosed |
| US-20070078157-A1 | Amine-based and amide-based inhibitors of semicarbazide-sensitive amine oxidase (SSAO)enzyme activity and VAP-1 mediated adhesion useful for treatment of diseases | LA JOLLA PHARMACEUTICAL COMPANY (US) | 2007-04-05 | — | — | US | disclosed |
| CN-1921841-A | Amines and amides for the treatment of diseases | JOLLA PHARMA (US) | 2007-02-28 | — | — | CN | disclosed |
| EP-1732531-A2 | AMINES AND AMIDES FOR THE TREATMENT OF DISEASES | LA JOLLA PHARMACEUTICAL COMPANY (US) | 2006-12-20 | — | — | EP | disclosed |
| US-20060025438-A1 | Amine-based and amide-based inhibitors of semicarbazide-sensitive amine oxidase (SSAO) enzyne activity and VAP-1 mediated adhesion useful for treatment of diseases | LA JOLLA PHARMACEUTICAL COMPANY | 2006-02-02 | — | — | US | disclosed |
| WO-2005082343-A2 | AMINES AND AMIDES FOR THE TREATMENT OF DISEASES | LA JOLLA PHARMACEUTICAL COMPANY (US) | 2005-09-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070078157-A1 | Amine-based and amide-based inhibitors of semicarbazide-sensitive amine oxidase (SSAO)enzyme activity and VAP-1 mediated adhesion useful for treatment of diseases | VCAM1, AOC2, AOC1 | TACR1 2071/4885MLYCD 1827/4885CYP3A4 3059/4885 |
| US-20120172392-A1 | AMINE-BASED AND AMIDE-BASED INHIBITORS OF SEMICARBAZIDE-SENSITIVE AMINE OXIDASE (SSAO) ENZYME ACTIVITY AND VAP-1 MEDIATED ADHESION USEFUL FOR TREATMENT OF DISEASES | VCAM1, AOC2, AOC1 | TACR1 2071/4885MLYCD 1827/4885CYP3A4 3059/4885 |
| US-20060025438-A1 | Amine-based and amide-based inhibitors of semicarbazide-sensitive amine oxidase (SSAO) enzyne activity and VAP-1 mediated adhesion useful for treatment of diseases | VCAM1, AOC3, AOC2 | TACR1 1355/4885MLYCD 2606/4885CYP3A4 3872/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.